Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?
Brain metastases (BM) are the most common intracranial neoplastic disease in adults, with an incidence of 9 –17% among all brain tumors (Nayak et al., 2012). They are usually caused by lung cancer (either non-small cell (NSCLC) and small cell (SCLC) histologies), breast cancer, melanoma and renal cell carcinoma, with a raising incidence related to the improvements in diagnostic and treatment approaches (Berghoff et al., 2014). However, prognosis remains poor, with a median overall survival (OS) ranging from 3 to 27 months (Brastianos et al., 2013), rendering BM still an unmet medical need.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Michele Porcu, Cinzia Solinas, Paolo Garofalo, Evandro de Azambuja, Mario Scartozzi, Karen Willard-Gallo, Matthias Preusser, Luca Saba Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Lung Cancer | Melanoma | Neurology | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer | Small Cell Lung Cancer